Zobrazeno 1 - 10
of 28
pro vyhledávání: '"M Dominguez-Cantero"'
Publikováno v:
Section 4: Clinical pharmacy services.
Publikováno v:
Section 4: Clinical pharmacy services.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J López-Santamaría Donoso, M Dominguez-Cantero, EM Barreiro-Fernandez, E Rios-Sanchez, MD Gil-Sierra
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
FJ Salmeron Navas, M Dominguez Cantero, EJ Alegre-Del Rey, Silvia Fénix-Caballero, EM Barreiro-Fernandez, C Moreno-Ramos
Publikováno v:
Section 1: Introductory statements and governance.
Background and importance ALK gene mutation occurs in 3–5% of patients with non-small cell lung cancer (NSCLC). Brigatinib and alectinib are potent ALK tyrosine kinase inhibitors, indicated in NSCLC. Aim and objectives The aim of this study was to
Autor:
B De La Calle-Riaguas, Gil-Sierra, Mdp Briceño-Casado, Marina Sánchez-Hidalgo, C Alarcon De La Lastra-Romero, EJ Alegre-Del Rey, M Dominguez-Cantero
Publikováno v:
Section 2: Selection, procurement and distribution.
Background and importance A greater benefit was suggested with early treatment with remdesivir against COVID-19. Aim and objectives To develop a systematic review and methodological interpretation of subgroup analyses according to timing of use of re
Autor:
Mdp Briceño Casado, FJ Juliá Luna, B De La Calle Riaguas, P Gómez Espinosa, M Dominguez Cantero
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance HIV infection causes premature aging. As a result, there is an increase in comorbidities and therapeutic burden in these patients earlier than in the rest of the population. Aim and objectives To evaluate the prevalence of p
Autor:
B De La Calle-Riaguas, Gil-Sierra, Mdp Briceño-Casado, C Alarcon De La Lastra-Romero, Silvia Fénix-Caballero, EJ Alegre-Del Rey, M Dominguez-Cantero, Marina Sánchez-Hidalgo
Publikováno v:
Section 2: Selection, procurement and distribution.
Background and importance There are studies (subgroup analyses) suggesting a lack of benefit for daratumumab drug combinations in patients with untreated multiple myeloma (MM) and hepatic impairment (HI). Aim and objectives To conduct a systematic se
Autor:
C Martínez Díaz, EM Barreiro Fernandez, EJ Alegre-Del Rey, FJ Salmeron Navas, M Dominguez Cantero, S. Fénix Caballero
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance The SARS-CoV-2 pandemic could have changed the clinical management of cancer patients because of travel restrictions, overloading of hospital systems and disruption of treatment. Lung cancer patients constitute a vulnerable
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Ixekizumab is a high affinity monoclonal antibody against interleukin 17A. It is used for the treatment of moderate-to-severe plaque psoriasis (MTSPP). Aim and objectives To assess the effectiveness and safety of ixekizumab